FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003089766> ?p ?o ?g. }

• W2003089766 endingPage "5132" @default.
• W2003089766 startingPage "5126" @default.
• W2003089766 abstract "Whereas the chimeric type I anti-CD20 Ab rituximab has improved outcomes for patients with B-cell malignancies significantly, many patients with non-Hodgkin lymphoma (NHL) remain incurable. Obinutuzumab (GA101) is a glycoengineered, humanized anti-CD20 type II Ab that has demonstrated superior activity against type I Abs in vitro and in preclinical studies. In the present study, we evaluated the safety, efficacy, and pharmacokinetics of GA101 in a phase 1 study of 21 patients with heavily pretreated, relapsed, or refractory CD20+ indolent NHL. Patients received GA101 in a dose-escalating fashion (3 per cohort, range 50/100-1200/2000 mg) for 8 × 21-day cycles. The majority of adverse events (AEs) were grades 1 and 2 (114 of 132 total AEs). Seven patients reported a total of 18 grade 3 or 4 AEs. Infusion-related reactions were the most common AE, with most occurring during the first infusion and resolving with appropriate management. Three patients experienced grade 3 or 4 drug-related infusion-related reactions. The best overall response was 43%, with 5 complete responses and 4 partial responses. Data from this study suggest that GA101 was well tolerated and demonstrated encouraging activity in patients with previously treated NHL up to doses of 2000 mg. This trial is registered at www.clinicaltrials.gov as NCT00517530." @default.
• W2003089766 created "2016-06-24" @default.
• W2003089766 creator A5003078312 @default.
• W2003089766 creator A5031977714 @default.
• W2003089766 creator A5033073385 @default.
• W2003089766 creator A5034473496 @default.
• W2003089766 creator A5036934183 @default.
• W2003089766 creator A5045374333 @default.
• W2003089766 creator A5051462303 @default.
• W2003089766 creator A5051605599 @default.
• W2003089766 creator A5084394194 @default.
• W2003089766 creator A5086354986 @default.
• W2003089766 creator A5086435750 @default.
• W2003089766 creator A5088215507 @default.
• W2003089766 date "2012-05-31" @default.
• W2003089766 modified "2023-10-17" @default.
• W2003089766 title "Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients" @default.
• W2003089766 cites W1685882185 @default.
• W2003089766 cites W1912693401 @default.
• W2003089766 cites W1996710470 @default.
• W2003089766 cites W2001302091 @default.
• W2003089766 cites W2018071905 @default.
• W2003089766 cites W2044360617 @default.
• W2003089766 cites W2058015212 @default.
• W2003089766 cites W2063792914 @default.
• W2003089766 cites W2065239231 @default.
• W2003089766 cites W2083435401 @default.
• W2003089766 cites W2091057822 @default.
• W2003089766 cites W2100151922 @default.
• W2003089766 cites W2101648653 @default.
• W2003089766 cites W2104940816 @default.
• W2003089766 cites W2109687784 @default.
• W2003089766 cites W2126529136 @default.
• W2003089766 cites W2127749132 @default.
• W2003089766 cites W2128964123 @default.
• W2003089766 cites W2135321054 @default.
• W2003089766 cites W2147047596 @default.
• W2003089766 cites W2154643481 @default.
• W2003089766 doi "https://doi.org/10.1182/blood-2012-01-404368" @default.
• W2003089766 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22431570" @default.
• W2003089766 hasPublicationYear "2012" @default.
• W2003089766 type Work @default.
• W2003089766 sameAs 2003089766 @default.
• W2003089766 citedByCount "174" @default.
• W2003089766 countsByYear W20030897662012 @default.
• W2003089766 countsByYear W20030897662013 @default.
• W2003089766 countsByYear W20030897662014 @default.
• W2003089766 countsByYear W20030897662015 @default.
• W2003089766 countsByYear W20030897662016 @default.
• W2003089766 countsByYear W20030897662017 @default.
• W2003089766 countsByYear W20030897662018 @default.
• W2003089766 countsByYear W20030897662019 @default.
• W2003089766 countsByYear W20030897662020 @default.
• W2003089766 countsByYear W20030897662021 @default.
• W2003089766 countsByYear W20030897662022 @default.
• W2003089766 countsByYear W20030897662023 @default.
• W2003089766 crossrefType "journal-article" @default.
• W2003089766 hasAuthorship W2003089766A5003078312 @default.
• W2003089766 hasAuthorship W2003089766A5031977714 @default.
• W2003089766 hasAuthorship W2003089766A5033073385 @default.
• W2003089766 hasAuthorship W2003089766A5034473496 @default.
• W2003089766 hasAuthorship W2003089766A5036934183 @default.
• W2003089766 hasAuthorship W2003089766A5045374333 @default.
• W2003089766 hasAuthorship W2003089766A5051462303 @default.
• W2003089766 hasAuthorship W2003089766A5051605599 @default.
• W2003089766 hasAuthorship W2003089766A5084394194 @default.
• W2003089766 hasAuthorship W2003089766A5086354986 @default.
• W2003089766 hasAuthorship W2003089766A5086435750 @default.
• W2003089766 hasAuthorship W2003089766A5088215507 @default.
• W2003089766 hasBestOaLocation W20030897661 @default.
• W2003089766 hasConcept C112705442 @default.
• W2003089766 hasConcept C126322002 @default.
• W2003089766 hasConcept C143998085 @default.
• W2003089766 hasConcept C18031839 @default.
• W2003089766 hasConcept C197934379 @default.
• W2003089766 hasConcept C2776694085 @default.
• W2003089766 hasConcept C2777063308 @default.
• W2003089766 hasConcept C2777525834 @default.
• W2003089766 hasConcept C2777607594 @default.
• W2003089766 hasConcept C2779338263 @default.
• W2003089766 hasConcept C2780653079 @default.
• W2003089766 hasConcept C71924100 @default.
• W2003089766 hasConcept C90924648 @default.
• W2003089766 hasConceptScore W2003089766C112705442 @default.
• W2003089766 hasConceptScore W2003089766C126322002 @default.
• W2003089766 hasConceptScore W2003089766C143998085 @default.
• W2003089766 hasConceptScore W2003089766C18031839 @default.
• W2003089766 hasConceptScore W2003089766C197934379 @default.
• W2003089766 hasConceptScore W2003089766C2776694085 @default.
• W2003089766 hasConceptScore W2003089766C2777063308 @default.
• W2003089766 hasConceptScore W2003089766C2777525834 @default.
• W2003089766 hasConceptScore W2003089766C2777607594 @default.
• W2003089766 hasConceptScore W2003089766C2779338263 @default.
• W2003089766 hasConceptScore W2003089766C2780653079 @default.
• W2003089766 hasConceptScore W2003089766C71924100 @default.
• W2003089766 hasConceptScore W2003089766C90924648 @default.
• W2003089766 hasIssue "22" @default.
• W2003089766 hasLocation W20030897661 @default.

• next